31 results
DEFM14A
CFMS
Conformis Inc
24 Jul 23
Proxy related to merger
8:00am
) of the Company Disclosure Letter, the FDA has not mandated that any Acquired Company recall any of its Products. There are no voluntary recalls of any
PREM14A
CFMS
Conformis Inc
14 Jul 23
Preliminary proxy related to merger
4:28pm
Company recall any of its Products. There are no voluntary recalls of any of the Acquired Company’s Products contemplated by any of the Acquired Companies
DEFA14A
CFMS
Conformis Inc
26 Jun 23
Additional proxy soliciting materials
5:25pm
, the FDA has not mandated that any Acquired Company recall any of its Products. There are no voluntary recalls of any of the Acquired Company’s Products
8-K
EX-2.1
CFMS
Conformis Inc
23 Jun 23
Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash
7:45am
has not mandated that any Acquired Company recall any of its Products. There are no voluntary recalls of any of the Acquired Company’s Products
8-K
EX-10.1
1f35wasg
23 Nov 21
Entry into a Material Definitive Agreement
5:00pm
424B5
cy8qsm
25 Sep 20
Prospectus supplement for primary offering
4:08pm
424B5
vamcje
6 Aug 20
Prospectus supplement for primary offering
12:00am
424B5
rgj8r kxgi3ncyzzwy
6 Aug 20
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
t35l jeca0aj4a
23 Mar 20
Conformis Announces Actions to Mitigate COVID-19 Impact
7:48am
8-K
6fq9xnp
23 Mar 20
Conformis Announces Actions to Mitigate COVID-19 Impact
7:48am
8-K
EX-10.1
pq2 qeh4e
26 Jun 19
Conformis Secures Up to $30 Million in Debt Financing and $3 Million in Equity Financing from Innovatus Life Sciences and East West Bank
12:00am
424B5
4lhyc mpz7w
18 Dec 18
Prospectus supplement for primary offering
2:22pm